当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > The sensitivity to methylnitrosourea-induced T-cell leukemogenesis in mice is modified by the injection of hydrocortisone.

The sensitivity to methylnitrosourea-induced T-cell leukemogenesis in mice is modified by the injection of hydrocortisone.

Abstract：

:T-cell leukemias were induced in adult BDF1 mice by a single i.v. injection of methylnitrosourea (MNU). Leukemogenesis was delayed by a single or repeated injections of hydrocortisone (HC) after MNU and also when HC was given one day before MNU. Enhancement of leukemogenesis was seen in experiments with 10 and 14 days' intervals between HC and MNU. The T-cell subset composition of the thymus after HC treatment was studied at these time intervals, but a specific target cell for the action of MNU, reduced one day after HC and increased in number during the thymic regeneration at 10 and 14 days could not be defined. HC did not prohibit the toxic action of MNU as measured by hemopoietic stem cell numbers in the femur.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Seidel HJ,Kreja L

doi

10.1016/0145-2126(85)90143-2

subject

Has Abstract

pub_date

1985-01-01 00:00:00

pages

625-9

issue

5

eissn

0145-2126

issn

1873-5835

pii

0145-2126(85)90143-2

journal_volume

9

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Monosomy 7 and Ph-positive acute lymphoblastic leukaemia: cytogenetic and molecular aspects.

    abstract：:A combination of monosomy 7 and translocation t(9;22) (q34;q11), rarely observed in acute lymphoblastic leukaemia (ALL), is here reported: a peculiarity of this case was that the "breakpoint cluster region" on chromosome 22 was not rearranged, as demonstrated by molecular analysis, and a new c-abl protein (p190) was f...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90114-7

    authors： Eridani S,Gorman P,Sheer D,Duncombe AS,Glass UH,Shivji MK

    更新日期：1987-01-01 00:00:00

  • Interleukin 4 production by peripheral blood lymphocytes in patients with classical Hodgkin lymphoma.

    abstract：:Although the production of interleukin (IL) 2 and interferon (IFN) gamma by peripheral blood lymphocytes in patients with Hodgkin lymphoma (HL) is well documented, the synthesis of IL4 has not been investigated before. The present study examines the production of IL4 by 2-day phytohaemaglutinin (PHA)-stimulated periph...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(03)00216-9

    authors： Mainou-Fowler T,Proctor SJ,Taylor PR

    更新日期：2004-02-01 00:00:00

  • Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele.

    abstract：:Predisposition to lymphomagenesis is a well-known phenomenon of ataxia-telangiectasia, a recessive disorder caused by germline inactivation of ATM. ATM encodes a protein implicated in the repair of radiation induced double-strand breaks. Biallelic ATM inactivation was described also in sporadic lymphoid malignancies, ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.11.010

    authors： Briani C,Schlotter M,Lichter P,Kalla C

    更新日期：2006-09-01 00:00:00

  • Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBFbeta/MYH11 after autologous transplantation: undetectable fusion transcript in pretransplant progenitor cells.

    abstract：:We describe here a unique case of therapy-related myelodysplastic syndrome (t-MDS) with inv(16)(p13q22) after autologous stem cell transplantation for lymphoma. The rare and smallest I type CBFbeta/MYH11 fusion transcript with a breakpoint at nucleotide 399 of CBFbeta and at nucleotide 2134 of MYH11 was detected in th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.08.001

    authors： Yamamoto K,Nishikawa S,Minagawa K,Yakushijin K,Okamura A,Matsui T

    更新日期：2006-03-01 00:00:00

  • Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.

    abstract：:Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.02.002

    authors： Cividin M,Ayrault O,Sorel N,Séité P,Brizard F,Blanchet O,Mahon FX,Guilhot F,Larsen C,Chomel JC,Brizard A

    更新日期：2006-10-01 00:00:00

  • Low plasma stem cell factor levels correlate with in vitro leukemic growth in myelodysplastic syndromes.

    abstract：:We evaluated the effect of SCF on myeloid differentiation by correlating clonogenic potential (as CFU-GM), bone marrow (BM) plasma SCF levels and CD34/c-kit expression in 57 MDS samples. There was a significant correlation between low SCF levels and 'leukemic' in vitro growth, the number of clusters and the colony/clu...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00175-1

    authors： Cortelezzi A,Cattaneo C,Cristiani S,Sarina B,Pomati M,Silvestris I,Ibatici A,Maiolo AT

    更新日期：1999-03-01 00:00:00

  • Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.

    abstract：:The methylation inhibitor decitabine (DAC) has great therapeutic value for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, DAC monotherapy is associated with relatively low rates of overall response and complete remission. Previous studies have shown promising results for combination treatmen...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.002

    authors： Geng S,Yao H,Weng J,Tong J,Huang X,Wu P,Deng C,Li M,Lu Z,Du X

    更新日期：2016-05-01 00:00:00

  • The role of low-dose chemotherapy in myelodysplastic syndromes.

    abstract：:Aggressive chemotherapy of myelodysplastic syndromes is rarely feasible because these disorders predominantly occur in elderly patients who often have concurrent illnesses. Alternative treatment modalities must therefore be evaluated. This review summarizes the results that have been obtained with low-dose chemotherap...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(92)90058-f

    authors： Aul C,Gattermann N

    更新日期：1992-01-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • The relationship between the site of breakpoints within the bcr gene and thrombopoiesis of Philadelphia-positive chronic myelocytic leukemia.

    abstract：:We determined the position of the breakpoint within the bcr gene in 22 patients with Philadelphia-positive chronic myelocytic leukemia using conventional Southern-blots and analyzed its relationship to thrombopoiesis. After DNA digestion with restriction endonucleases (Hind III, Bam HI and Bgl II), we localized the br...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90113-8

    authors： Inokuchi K,Futaki M,Yamada T,Tanabe Y,Dan K,Shinohara T,Kuriya S,Nomura T

    更新日期：1991-01-01 00:00:00

  • Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.

    abstract：:We investigated the possible influence of recombinant (r) sIL-6R on the growth of three IL-6 non-responsive or weakly IL-6 responsive long-term myeloma cell lines. The three cell lines chosen for the study (U266, L363 and Fravel) all expressed gp130 but differed in their expression of IL-6R and IL-6. mRNA analysis by ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00077-1

    authors： Diamant M,Hansen MB,Rieneck K,Svenson M,Yasukawa K,Bendtzen K

    更新日期：1996-04-01 00:00:00

  • The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.

    abstract：:HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for hete...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.03.016

    authors： Lazenby M,Hills R,Burnett AK,Zabkiewicz J

    更新日期：2015-06-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations.

    abstract：:We investigated the transcript levels of genes STAT1, STAT3, STAT5A and STAT5B in the diagnostic samples of childhood ALL patients and compared them to those of healthy controls in order to characterize STAT gene expression in childhood ALL. As compared to controls, ALL patients exhibit markedly decreased transcript l...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.09.004

    authors： Adamaki M,Tsotra M,Vlahopoulos S,Zampogiannis A,Papavassiliou AG,Moschovi M

    更新日期：2015-09-11 00:00:00

  • Identification of PML-RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH.

    abstract：:Acute promyelocytic leukemia (APL) is characterized by a reciprocal translocation, t(15;17) (q22;q12), resulting in fusion of the genes promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARA). With conventional cytogenetic methods, these translocations are detected in about 70-90% of patients, with most o...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.05.011

    authors： Han JY,Kim KE,Kim KH,Park JI,Kim JS

    更新日期：2007-02-01 00:00:00

  • Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.

    abstract：BACKGROUND:Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. F...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.01.002

    authors： Xiao D,Shi Y,Fu C,Jia J,Pan Y,Jiang Y,Chen L,Liu S,Zhou W,Zhou J,Tao Y

    更新日期：2016-03-01 00:00:00

  • Physical and functional interactions between hematopoietic cell-specific ETS transcription factors and homeodomain proteins.

    abstract：:To examine the possibility that ETS family transcription factors, PU.1, SPI-B, ELF-1, ERG-3, ETS-1 and TEL, and homeodomain proteins, HOXA10, HOXC13, MEIS1 and PBX1B, function cooperatively, we investigated their interactions. In luciferase assays, HOXA10 and HOXC13 augmented the activity of PU.1 and SPI-B while dimin...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.07.002

    authors： Yamada T,Shimizu T,Sakurai T,Nanashima N,Kihara-Negishi F,Suzuki M,Fan Y,Akita M,Oikawa T,Tsuchida S

    更新日期：2009-03-01 00:00:00

  • Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.

    abstract：:Leukemic bcr-abl positive dendritic cells (DCs) are likely to be present in vivo in chronic myelogenous leukemia (CML) patients, but no data are available on their functional qualities. We analyzed the circulating BDCA-1+ myeloid DC compartment in 15 chronic phase CML patients. Phenotypic features of CML DCs were comp...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.11.028

    authors： Orsini E,Calabrese E,Maggio R,Pasquale A,Nanni M,Trasarti S,Tafuri A,Guarini A,Foa R

    更新日期：2006-07-01 00:00:00

  • Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.

    abstract：:Outcomes in patients with secondary acute myeloid leukemia (sAML) (including therapy related myeloid neoplasms and AML with myelodysplasia related changes (MRC)) are poor. Patients treated with hypomethylating agents (HMAs) for antecedent hematological malignancy (AHM) have suboptimal responses to induction chemothera...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2020.106367

    authors： Talati C,Goldberg AD,Przespolewski A,Chan O,Ali NA,Kim J,Famulare C,Sallman D,Padron E,Kuykendall A,Lancet JE,Wang E,Tallman MS,Komrokji R,Sweet K

    更新日期：2020-06-01 00:00:00

  • Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.

    abstract：:Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2014.02.008

    authors： Mark TM,Coleman M,Niesvizky R

    更新日期：2014-05-01 00:00:00

  • Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.

    abstract：:Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Co...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2019.02.009

    authors： King AC,Pappacena JJ,Tallman MS,Park JH,Geyer MB

    更新日期：2019-04-01 00:00:00

  • Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.

    abstract：:Accumulation of cytosine arabinoside triphosphate (araCTP) from a range of cytosine arabinoside (araC) concentrations (1-50 microM) was measured during incubations of leukemic cells freshly isolated from patients with acute leukemia. In all but one patient, increments in extracellular araC above 10 microM did not incr...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90035-8

    authors： Jamieson GP,Snook MB,Wiley JS

    更新日期：1990-01-01 00:00:00

  • Regular analgesic use and risk of multiple myeloma.

    abstract：:Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence mat...

    journal_title：Leukemia research

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.leukres.2006.07.027

    authors： Moysich KB,Bonner MR,Beehler GP,Marshall JR,Menezes RJ,Baker JA,Weiss JR,Chanan-Khan A

    更新日期：2007-04-01 00:00:00

  • Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

    abstract：:The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KITwt); and AML wi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.12.012

    authors： Strickland SA,Shaver AC,Byrne M,Daber RD,Ferrell PB,Head DR,Mohan SR,Mosse CA,Moyo TK,Stricker TP,Vnencak-Jones C,Savona MR,Seegmiller AC

    更新日期：2018-02-01 00:00:00

  • Comparison of ethidium bromide-stained agarose gel electrophoresis and automated fragment analysis for evaluation of IgH gene products.

    abstract：:In acute lymphoblastic leukemia (ALL) patients, automated fluorescence fragment analysis (ALF) has been reported to improve the monoclonality detection rate of immunoglobulin heavy chain genes (IgH) polymerase chain reaction (PCR) analysis. This study performed complementary determining region (CDR) I and III PCR on s...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00025-x

    authors： Gleissner B,Maurer J,Sindram A,Reinhard R,Thiel E

    更新日期：2001-09-01 00:00:00

  • Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

    abstract：:Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.03.036

    authors： Zhang Y,Wang Z,Zhang J,Farmer B,Lim SH

    更新日期：2008-12-01 00:00:00

  • MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia.

    abstract：BACKGROUND:Monocyte chemoattractant protein-1 (MCP-1) is a member of the CC chemokines. MCP-1 has been previously shown to have a major role in the migration of monocytes towards human leukemic cells, yet it cannot increase cytotoxic effects of monocytes on human leukemic cells. AIM:To determine levels of MCP-1 in the...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.01.017

    authors： Eisenkraft A,Keidan I,Bielorai B,Keller N,Toren A,Paret G

    更新日期：2006-10-01 00:00:00

  • Leukotrienes and lipoxins--new potential performers in the regulation of human myelopoiesis.

    abstract：:Leukotrienes and lipoxins are bioactive lipoxygenase products formed by leukocytes alone or in collaboration with other cells. While the physiological role of lipoxins remains to be clarified, accumulating evidence shows that leukotrienes are important mediators in asthma and inflammation. Consequently, recent clinica...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(94)90053-1

    authors： Stenke L,Reizenstein P,Lindgren JA

    更新日期：1994-10-01 00:00:00

  • Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression.

    abstract：:Deregulated myc, bcl-2 and/or TP53 gene expression is associated with non-Hodgkin's B cell lymphomas (B-NHLs). Emu-N-myc transgenic mice that misexpress N-myc protein and carry a non-disrupted bcl-2 gene develop indolent B cell lymphomas reminiscent of the B-NHL, follicular lymphoma. Tumors from mice with end-stage di...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00103-4

    authors： Samant SA,Sheppard RD

    更新日期：1999-10-01 00:00:00

  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

    abstract：:Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.10.025

    authors： Moore J,Seiter K,Kolitz J,Stock W,Giles F,Kalaycio M,Zenk D,Marcucci G

    更新日期：2006-07-01 00:00:00